Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$0.28
+9.0%
$0.27
$0.20
$1.48
$67.06M2.181.63 million shs906,181 shs
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
$1.29
$1.22
$0.93
$3.42
$64.44M1.36406,955 shsN/A
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
$1.09
-4.1%
$0.88
$0.51
$1.60
$63.06M-0.257,461 shs152,741 shs
Nicox SA stock logo
NICXF
Nicox
$0.25
$0.25
$0.25
$0.28
$17.23M0.29N/AN/A
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
+9.01%+13.78%-2.09%+28.28%-77.02%
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
0.00%-4.44%+15.18%+14.16%-37.38%
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
-4.08%+0.80%+39.39%+70.41%-16.26%
Nicox SA stock logo
NICXF
Nicox
0.00%0.00%0.00%0.00%-43.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
2.1413 of 5 stars
3.15.00.00.01.30.80.0
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
1.6029 of 5 stars
3.03.00.00.00.01.70.6
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
3.3195 of 5 stars
3.55.00.00.01.52.50.6
Nicox SA stock logo
NICXF
Nicox
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
2.29
Hold$1.35390.09% Upside
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
2.00
Hold$2.5194.26% Upside
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
3.00
Buy$7.00543.03% Upside
Nicox SA stock logo
NICXF
Nicox
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NICXF, AKYA, ADAP, and CNTB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$1.50 ➝ $0.50
6/12/2025
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$7.00
5/19/2025
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$1.80 ➝ $1.08
5/14/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.00
5/14/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.46
4/29/2025
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$3.50 ➝ $1.80
4/14/2025
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$2.40 ➝ $1.65
4/11/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$178.03M0.41N/AN/A$0.05 per share5.52
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
$81.67M0.79N/AN/A$0.15 per share8.60
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
$26.03M2.32N/AN/A$1.67 per share0.65
Nicox SA stock logo
NICXF
Nicox
$5.52M3.12N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$70.81M-$0.27N/AN/AN/A-38.91%-163.73%-23.65%8/11/2025 (Estimated)
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
-$55.37M-$0.97N/AN/AN/A-59.44%-487.85%-35.86%8/4/2025 (Estimated)
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
-$15.63MN/A0.00N/AN/AN/AN/AN/A9/5/2025 (Estimated)
Nicox SA stock logo
NICXF
Nicox
-$29.25MN/A0.00N/AN/AN/AN/A7/16/2025 (Estimated)

Latest NICXF, AKYA, ADAP, and CNTB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
-$0.22N/AN/AN/A$18.10 millionN/A
5/15/2025Q1 2025
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
-$0.26-$0.19+$0.07-$0.19N/AN/A
5/13/2025Q1 2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million
5/12/2025Q1 2025
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
-$0.29-$0.32-$0.03-$0.32$20.19 million$16.64 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
N/AN/AN/AN/AN/A
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
N/AN/AN/AN/AN/A
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
N/AN/AN/AN/AN/A
Nicox SA stock logo
NICXF
Nicox
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
4.24
2.02
1.79
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
10.12
0.61
0.40
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
0.01
10.25
10.25
Nicox SA stock logo
NICXF
Nicox
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
31.37%
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
79.42%
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
58.72%
Nicox SA stock logo
NICXF
Nicox
N/A

Insider Ownership

CompanyInsider Ownership
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
12.74%
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
7.30%
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
22.60%
Nicox SA stock logo
NICXF
Nicox
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
490265.05 million231.28 millionOptionable
Akoya Biosciences, Inc. stock logo
AKYA
Akoya Biosciences
9049.95 million46.31 millionOptionable
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
11055.56 million43.00 millionOptionable
Nicox SA stock logo
NICXF
Nicox
2868.92 millionN/ANot Optionable

Recent News About These Companies

NicOx S.A.
Nicox Provides Full Year 2024 Financial Results
NICOX SA: Nicox Extends Cash Runway into Q4 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptimmune Therapeutics stock logo

Adaptimmune Therapeutics NASDAQ:ADAP

$0.28 +0.02 (+9.01%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$0.28 0.00 (-0.29%)
As of 06:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Akoya Biosciences stock logo

Akoya Biosciences NASDAQ:AKYA

$1.29 0.00 (0.00%)
As of 07/8/2025

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Connect Biopharma stock logo

Connect Biopharma NASDAQ:CNTB

$1.09 -0.05 (-4.08%)
Closing price 07/9/2025 03:59 PM Eastern
Extended Trading
$1.25 +0.16 (+14.83%)
As of 06:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Nicox stock logo

Nicox OTCMKTS:NICXF

$0.25 0.00 (0.00%)
As of 07/8/2025

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.